Role of radiation therapy in the management of cutaneous malignant melanoma

Eyal Fenig*, Efraim Eidelevich, Eliud Njuguna, Alan Katz, Haim Gutman, Aaron Sulkes, Jacob Schechter

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Traditionally, cutaneous malignant melanoma is regarded as a radioresistant tumor. Recently, however, an increasing number of clinical studies have refuted this notion. The authors examined the role of radiation therapy in the palliative and/or adjuvant treatment of cutaneous malignant melanoma. The records of 69 patients with cutaneous malignant melanoma were reviewed. Twenty-five patients with extensive regional lymph node involvement received adjuvant radiation therapy after primary surgical treatment, and the remainder received palliative radiation therapy. The therapeutic significance of fraction size was analyzed. In the palliative radiation therapy group, the response rate was 52% with a fraction size ≤300 cGy and 35% with a larger fraction size (p > 0.05, NS). Local regional control rates after adjuvant radiation therapy using conventional fractionation and larger fraction size were 87% and 82%, respectively (p > 0.05, NS). Radiation therapy is effective in the management of cutaneous malignant melanoma. It plays an important role in the palliation of metastatic disease and as an adjuvant treatment. No advantage in using a large fraction size over conventional dose schedules was found.

Original languageEnglish
Pages (from-to)184-186
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number2
StatePublished - Apr 1999
Externally publishedYes


  • Adjuvant therapy
  • Cutaneous malignant melanoma
  • Palliative treatment
  • Radiation therapy


Dive into the research topics of 'Role of radiation therapy in the management of cutaneous malignant melanoma'. Together they form a unique fingerprint.

Cite this